Annual Reports on Medicinal Chemistry
- 1 Edición, Volumen 66 - 1 de octubre de 2026
- Última edición
- Editor: Katherine Seley-Radtke
- Idioma: Inglés
Annual Reports in Medicinal Chemistry Volume 66 provides timely and critical reviews of important topics in medicinal chemistry, with an emphasis on emerging topics in the biolog… Leer más
Descripción
Descripción
Annual Reports in Medicinal Chemistry Volume 66 provides timely and critical reviews of important topics in medicinal chemistry, with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies. Focus in this new release is on The anti-inflammatory and immunological properties of GLP-1R and How to reduce side effects of GLP-1 based obesity medications.
Puntos claves
Puntos claves
- Contains contributions from leading authorities on the topics covered
- Informs and updates on all the latest developments in the field of medicinal chemistry
- Delves into the use of GLP-1s and side effect reduction
De interès para
De interès para
Ideally suited for chemists engaged in multidisciplinary teams for drug discovery; this includes medicinal chemists and others involved in chemical biology and bio-organic disciplines and computational chemistry
Índice
Índice
1: The anti-infiammatory and immunological properties of GLP-1R
2: GLP-1–based multipharmacology: biased signaling as a determinant of therapeutic efficacy
3: How to reduce side effects of GLP-1 based obesity medications
2: GLP-1–based multipharmacology: biased signaling as a determinant of therapeutic efficacy
3: How to reduce side effects of GLP-1 based obesity medications
Detalles del producto
Detalles del producto
- Edición: 1
- Última edición
- Volumen: 66
- Publicado: 1 de octubre de 2026
- Idioma: Inglés
Sobre el editor
Sobre el editor
KS
Katherine Seley-Radtke
Prof. Katherine Seley-Radtke group’s NIH-funded research employs a chemical biology approach to
nucleoside, nucleotide and heterocyclic drug discovery and development with therapeutic
emphasis on antiviral, anticancer and antiparasitic targets and overcoming resistance to currently
used drugs. Current focus is targeting Ebola, Zika, Dengue and MERS viruses. She has served as
the Program Director for UMBC’s Chemistry-Biology Interface graduate training program
funded by NIH since 2007. This program promotes hands on cross disciplinary research for
almost 50 PhD students from four departments at UMBC and UMB. She is currently the
Immediate Past President and Secretary-Elect for the International Society of Nucleosides,
Nucleotides and Nucleic Acids and a Board member of the International Society for Antiviral
Research. Prof. Seley-Radtke also serves as a standing member for several NIH study sections
and is an Associate Editor for three scientific journals – Antiviral Chemistry & Chemotherapy,
Molecules – Chemical Biology, and Current Protocols in Chemical Biology.
Afiliaciones y experiencia
Professor of Chemistry and Biochemistry, University of Maryland, Baltimore County, MD, USA